Bridge Biotherapeutics, an innovative new drug research and development company, will present the preclinical study results of BBT-207, a candidate for the 4th generation lung cancer target therapy, in poster form at the AACR Annual Meeting 2023 to be held in Orlando, Florida, USA next month announced that it would be announced.

According to the research abstract released on the society's homepage on the 14th local time, the company plans to present data on the anti-tumor efficacy of BBT-207 as well as its ability to inhibit brain metastases confirmed through the results of preclinical studies that have progressed over the past year.

BBT-207 is the first new drug candidate independently discovered by Bridge Biotherapeutics, a novel epidermal growth factor receptor that targets and treats resistance mutations that may appear after treatment with third-generation EGFR inhibitors such as Tagrisso (ingredient: osimertinib). It is a tyrosine kinase inhibitor (EGFR TKI; Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor).

The company presented preclinical data of BBT-207 in the form of a poster at the AACR held last year, revealing the pharmacokinetic properties of the drug explored based on cell lines and animal experiments, as well as inhibition of C797S-positive double mutations and various resistance mutations. there is. At this conference, based on the results of additional animal experiments, anti-tumor efficacy survival improvement in brain metastasis animal models, data related to brain metastasis inhibition, which examines the possibility of targeted treatment for C797S-positive mutations, are presented, and are expected to expand the treatment strategy currently in progress. The possibility of development as a 4th-generation non-small cell lung cancer targeted therapy that can respond to various mutations caused by the disease will be discussed.

Vice President Jimmy Jin, who is in charge of discovery biology at Bridge Biotherapeutics, said, 'Following the major preclinical data disclosed at the global conference stage last year, the excellent antitumor efficacy and brain metastasis model of BBT-207 at this year's stage as well. 'We observed the positive potential of BBT-207 as a 4th-generation lung cancer targeted therapy that can respond to various resistance mutations, which is a combination administration strategy with other treatment options. We expect it to be further strengthened through this,' he said.

As Tagrisso expands its scope as a first-line treatment for non-small cell lung cancer, the need for new treatment options targeting various mutations, such as the C797S-positive double mutation, is increasing. BBT-207 is being developed as a fourth-generation treatment that can respond to various resistance mutations, including the C797S-positive double mutation, and is developing with the goal of submitting a clinical trial plan (IND) to the US Food and Drug Administration (FDA) in the first half of this year. are accelerating

Meanwhile, Bridge Biotherapeutics is developing BBT-176, a first-in-class clinical stage candidate for the fourth-generation lung cancer targeting treatment for C797S-positive triple mutations. We are strengthening our efforts to develop innovative treatments for non-small cell lung cancer, such as continuing diagnostic research.

(C) 2023 Electronic News Publishing, source ENP Newswire